Bionano Genomics BNGO just pulled back the curtain on its fourth-quarter results, and the message is clear: the company is getting leaner while its technology goes deeper into the clinical mainstream.
The critics of Bionano (NASDAQ:BNGO) stock are ignoring and/or severely underestimating developments involving its DNA mapping tool, Saphyr. Source: Natali_ Mis/ShutterStock.com Specifically, there is ...
The average one-year price target for Bionano Genomics (NasdaqCM:BNGO) has been revised to $5.61 / share. This is a decrease of 26.67% from the prior estimate of $7.65 dated February 21, 2026. The ...
Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2025 Earnings Call Transcript March 23, 2026 Bionano Genomics, Inc. reports earnings inline with expectations. Reported EPS is $-2.475 EPS, expectations were ...
Bionano Genomics, Inc. reports earnings inline with expectations. Reported EPS is $-2.475 EPS, expectations were $-2.475. Operator: Good day, and welcome to the Bionano Genomics, Inc. Fourth Quarter ...
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ...
SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results